EMA consults on revised guideline on active substance master file procedure
This article was originally published in SRA
Executive Summary
The European Medicines Agency is consulting on proposed improvements to its guideline on how drug companies can compile an active substance master file (ASMF) and the "active substance section" of their dossiers for a marketing authorisation application or a marketing authorisation variation1.